The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. (4th May 2017)

• Record Type: Journal Article
• Authors: Paquet-Fifield, Sophie; Roufail, Sally; Zhang, You-Fang; Sofian, Trifina; Byrne, David J.; Coughlin, Paul B.; Fox, Stephen B.; Stacker, Steven A.; Achen, Marc G.
• Is Part Of: Growth factors. Volume 35:Number 2/3(2017)
• Page Start: 61
• Page End: 75
• Publication Date: 2017-05-04
• Subjects: Cancer -- lymphatic remodelling -- metastasis -- plasmin -- protease -- VEGF-D; Growth factors -- Periodicals; Physiology -- Periodicals; 611
• DOI: 10.1080/08977194.2017.1349765
• Languages: English
• ISSNs: 0897-7194

Abstract

Abstract: Remodelling of lymphatic vessels in tumours facilitates metastasis to lymph nodes. The growth factors VEGF-C and VEGF-D are well known inducers of lymphatic remodelling and metastasis in cancer. They are initially produced as full-length proteins requiring proteolytic processing in order to bind VEGF receptors with high affinity and thereby promote lymphatic remodelling. The fibrinolytic protease plasmin promotes processing of VEGF-C and VEGF-D in vitro, but its role in processing them in cancer was unknown. Here we explore plasmin's role in proteolytically activating VEGF-D in vivo, and promoting lymphatic remodelling and metastasis in cancer, by co-expressing the plasmin inhibitor α2 -antiplasmin with VEGF-D in a mouse tumour model. We show that α2 -antiplasmin restricts activation of VEGF-D, enlargement of intra-tumoural lymphatics and occurrence of lymph node metastasis. Our findings indicate that the fibrinolytic system influences lymphatic remodelling in tumours which is consistent with previous clinicopathological observations correlating fibrinolytic components with cancer metastasis.